The introduction of SARS-CoV-2 into the human population represents a tremendous medical and economic crisis. Innate immunity – as the first line of defense of our immune system – plays a central role in combating this novel virus. In this article, the authors provide a conceptual framework for the interaction of the human innate immune system with SARS-CoV-2 to link the clinical observations with experimental findings that have been made during the first year of the pandemic. We review evidence that variability in innate immune system components among humans is a main contributor to the heterogeneous disease courses observed for COVID-19. A better understanding of the pathophysiological mechanisms observed for cells and soluble mediators involved in innate immunity is a prerequisite for the development of diagnostic markers and therapeutic strategies targeting COVID-19. However, this will also require additional studies addressing causality of events, which is so far lacking.
DOI: https://doi.org/10.1016/j.cell.2021.02.029